Yongchang Zhang, MD
Hunan Cancer Hospital · Hunan Province Tumor Hospital · zhangyongchang@csu.edu.cn
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
30
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in non-small cell lung cancer
0
PubMed author-name match
Trials
Studies that name Yongchang Zhang, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07878871 · Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II StudyHunan Province Tumor Hospital · not yet recruiting · Lung Adenocarcinoma, Stage III Lung Cancer, EGFR Positive Non-small Cell Lung Cancer · principal investigator
- N/ANCT06174857 · Efficacy of Osimertinib in Patients With Lung CancerHunan Province Tumor Hospital · unknown · Advanced Non-Small Cell Lung Cancer · principal investigator
- N/ANCT05984017 · A Non-interventional Study With Advanced Lung Squamous Cell CarcinomaHunan Province Tumor Hospital · unknown · Advanced Lung Squamous Cell Carcinoma · principal investigator
- Ph3NCT05549037 · Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLCHunan Province Tumor Hospital · completed · Non-small Cell Lung Cancer · principal investigator
- N/ANCT05450081 · Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in PatientsHunan Province Tumor Hospital · completed · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT05284539 · Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung CancerHunan Province Tumor Hospital · recruiting · Non Small Cell Lung Cancer · principal investigator
- N/ANCT05261438 · Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCHunan Province Tumor Hospital · completed · Non-squamous NSCLC · principal investigator
- N/ANCT05129462 · Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC PatientsHunan Province Tumor Hospital · completed · Non Small Cell Lung Cancer · principal investigator
- N/ANCT05059951 · Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung CancerHunan Province Tumor Hospital · recruiting · Non Small Cell Lung Cancer · principal investigator
- Ph3NCT05055908 · Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsHunan Province Tumor Hospital · recruiting · Lung Cancer · principal investigator
- N/ANCT05055999 · Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung CancerHunan Province Tumor Hospital · completed · Extensive Stage Small Cell Lung Cancer · principal investigator
- N/ANCT05055947 · Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung CancerHunan Province Tumor Hospital · completed · Extensive Stage Small Cell Lung Cancer · principal investigator
- N/ANCT05023837 · Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological TypeHunan Province Tumor Hospital · completed · Uncommon Pathological Types of Lung Cancer · principal investigator
- Ph2NCT05014464 · ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell CarcinomaHunan Province Tumor Hospital · recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04997382 · Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLCHunan Province Tumor Hospital · completed · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04951947 · JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung CancerHunan Province Tumor Hospital · unknown · Small-cell Lung Cancer · principal investigator
- Ph2NCT04937972 · SHR-1701 Combined With Fluzoparib in Lung Squamous Cell CarcinomaHunan Province Tumor Hospital · unknown · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT04777084 · The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.Hunan Province Tumor Hospital · recruiting · Non-Small Cell Lung Cancer · principal investigator
- N/ANCT04324164 · Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLCHunan Province Tumor Hospital · recruiting · Non-small Cell Lung Cancer · principal investigator
- N/ANCT04324125 · Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLCHunan Province Tumor Hospital · unknown · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT04322578 · Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLCHunan Province Tumor Hospital · unknown · Non-small Cell Lung Cancer · principal investigator
- N/ANCT04322591 · Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON TrialHunan Province Tumor Hospital · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04322890 · Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationHunan Province Tumor Hospital · recruiting · Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation · principal investigator
- Ph2/Ph3NCT04322617 · Anlotinib Plus Immune Checkpoint Inhibitors for Lung CancerHunan Province Tumor Hospital · recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04144569 · PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLCYongchang Zhang · unknown · HER2 Insertion Mutation Positive Advanced NSCLC · principal investigator
- Ph2NCT03798743 · Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS StudyHunan Province Tumor Hospital · completed · Non-small Cell Lung Cancer · principal investigator
- N/ANCT03647098 · Survival Outcomes of Lung CancerHunan Province Tumor Hospital · recruiting · Lung Cancer · principal investigator
- N/ANCT03647111 · Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung CancerHunan Province Tumor Hospital · unknown · Non-small Cell Lung Cancer · principal investigator
- N/ANCT03646994 · Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung CancerHunan Province Tumor Hospital · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT03646968 · Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save StudyYongchang Zhang · unknown · Non-Squamous Non Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.